The future trajectory of adverse outcome pathways: a commentary

被引：0

作者：

Fiona Sewell

Nichola Gellatly

Maria Beaumont

Natalie Burden

Richard Currie

Lolke de Haan

Thomas H. Hutchinson

Miriam Jacobs

Catherine Mahony

Ian Malcomber

Jyotigna Mehta

Graham Whale

Ian Kimber

机构：

[1] National Centre for the Replacement,School of Geography, Earth and Environmental Sciences

[2] Refinement and Reduction of Animals in Research (NC3Rs),Faculty of Biology, Medicine and Health

[3] GlaxoSmithKline,undefined

[4] Syngenta Ltd.,undefined

[5] Jealott’s Hill International Research Centre,undefined

[6] MedImmune,undefined

[7] University of Plymouth,undefined

[8] Public Health England,undefined

[9] Procter and Gamble Company,undefined

[10] Unilever,undefined

[11] Safety and Environmental Assurance Centre,undefined

[12] Dow AgroSciences,undefined

[13] European Development Centre,undefined

[14] Shell,undefined

[15] Health,undefined

[16] Shell Centre,undefined

[17] University of Manchester,undefined

来源：

Archives of Toxicology | 2018年 / 92卷

关键词：

Adverse outcome pathways (AOPs); Hazard identification; Safety assessment; Risk assessment;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The advent of adverse outcome pathways (AOPs) has provided a new lexicon for description of mechanistic toxicology, and a renewed enthusiasm for exploring modes of action resulting in adverse health and environmental effects. In addition, AOPs have been used successfully as a framework for the design and development of non-animal approaches to toxicity testing. Although the value of AOPs is widely recognised, there remain challenges and opportunities associated with their use in practise. The purpose of this article is to consider specifically how the future trajectory of AOPs may provide a basis for addressing some of those challenges and opportunities.

引用

页码：1657 / 1661

页数：4

共 50 条

[11] Are Adverse Outcome Pathways Here to Stay?
Garcia-Reyero, Natalia
ENVIRONMENTAL SCIENCE & TECHNOLOGY, 2015, 49 (01) : 3 - 9
[12] REVERSE ENGINEERING ADVERSE OUTCOME PATHWAYS
Perkins, Edward J.
Chipman, J. Kevin
Edwards, Stephen
Habib, Tanwir
Falciani, Francesco
Taylor, Ronald
Van Aggelen, Graham
Vulpe, Chris
Antczak, Philipp
Loguinov, Alexandre
ENVIRONMENTAL TOXICOLOGY AND CHEMISTRY, 2011, 30 (01) : 22 - 38
[13] Adverse Outcome Pathways in Computational Toxicology
Kleinstreuer, N. C.
BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY, 2013, 97 (05) : 278 - 278
[14] Semantic characterization of adverse outcome pathways
Wang, Rong-Lin
AQUATIC TOXICOLOGY, 2020, 222
[15] Adverse Outcome Pathways: Background and Principles
Munn, S. J.
TOXICOLOGY LETTERS, 2019, 314 : S2 - S2
[16] Adverse Outcome Pathways for Engineered Systems
Salter, R. Cody
Garcia-Reyero, Natalia
Ruvinsky, Alicia
Seale, Maria
Perkins, Edward
2023 IEEE INTERNATIONAL SYSTEMS CONFERENCE, SYSCON, 2023,
[17] Adverse outcome pathways: hype or hope?
Vinken, Mathieu
Whelan, Maurice
Rogiers, Vera
ARCHIVES OF TOXICOLOGY, 2014, 88 (01) : 1 - 2
[18] Creating Quantitative Adverse Outcome Pathways with Effectopedia
Aladjov, H. T.
TOXICOLOGY LETTERS, 2018, 295 : S11 - S11
[19] Adverse Outcome Pathways and the Paradox of Complex Simplicity
Knapen, Dries
ENVIRONMENTAL TOXICOLOGY AND CHEMISTRY, 2021, 40 (11) : 2950 - 2952
[20] Skin Sensitisation, Adverse Outcome Pathways and Alternatives
Basketter, David
ATLA-ALTERNATIVES TO LABORATORY ANIMALS, 2016, 44 (05): : 431 - 436

← 1 2 3 4 5 →